Taken together, our data indicated that AFAP1-AS1 might be an oncogenic lncRNA that promoted GC progression by functioning as a ceRNA to regulate FGF7 expression via sponging miR-155-5p, suggesting AFAP1-AS1 might be a novel potential therapeutic target for GC. The gene discussed is FGF7; the disease is gastric cancer.